Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Capital Expenditures: 2013-2025

Historic Capital Expenditures for Amphastar Pharmaceuticals (AMPH) over the last 12 years, with Sep 2025 value amounting to $5.3 million.

  • Amphastar Pharmaceuticals' Capital Expenditures fell 61.23% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.0 million, marking a year-over-year increase of 2.49%. This contributed to the annual value of $41.0 million for FY2024, which is 7.53% up from last year.
  • Amphastar Pharmaceuticals' Capital Expenditures amounted to $5.3 million in Q3 2025, which was down 49.38% from $10.6 million recorded in Q2 2025.
  • Amphastar Pharmaceuticals' 5-year Capital Expenditures high stood at $13.8 million for Q3 2024, and its period low was $5.3 million during Q3 2025.
  • Moreover, its 3-year median value for Capital Expenditures was $9.5 million (2023), whereas its average is $9.6 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first spiked by 81.27% in 2023, then tumbled by 61.23% in 2025.
  • Amphastar Pharmaceuticals' Capital Expenditures (Quarterly) stood at $6.9 million in 2021, then declined by 8.26% to $6.3 million in 2022, then soared by 49.64% to $9.4 million in 2023, then soared by 31.44% to $12.4 million in 2024, then tumbled by 61.23% to $5.3 million in 2025.
  • Its Capital Expenditures was $5.3 million in Q3 2025, compared to $10.6 million in Q2 2025 and $10.7 million in Q1 2025.